Xenon Pharmaceuticals

Canada
Burnaby, British Columbia, Canada, V5G 4W8

Company profile

Xenon Pharmaceuticals company profile

Xenon Pharmaceuticals is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform, which we refer to as Extreme Genetics. Our product candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits or phenotypes. They apply their expertise to predict which phenotypes are caused by single-gene defects. By identifying and characterizing the single-gene defects responsible for such severe phenotypes, they gain valuable insights into their function in human biology and their potential as drug targets. Given that these targets are often involved in diseases beyond the rare genetic disorders in which they are first identified, they are developing proprietary product candidates to treat both orphans as well as more prevalent diseases

Business identity

Contact email
[email protected]
Phone number
(604) 484-3300
Operating status
Active
Company type
For Profit
Employee range
101-250 employees
Revenue range
$0-$1M
Founded
1996-01-01, Year

Headquarters

Postal code
V5G 4W8
Country code
CA
Continent
North America

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
12
Total equity funding
$1.3B
Last funding
Post IPO Equity / $300M / 2023-11-29
Last equity funding
Post IPO Equity / $300M
Investors
10
Lead investors
1
Founders
1
Articles
112
Exited on
2014-11-05

Founders and investors

Founders

Simon Pimstone

Lead investors

Neurocrine Biosciences

Investors

JPMorgan PartnersNeurocrine BiosciencesNew Enterprise AssociatesNorthview LifeSciencesTakeda